Clinical trials
Observational Fabry Disease trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2008 | 1 |
| 2018 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 8 |
| Completed | 6 |
| Terminated | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 4 |
| Chiesi Farmaceutici S.p.A. | 2 |
| Chiesi Italia | 2 |
| CENTOGENE GmbH Rostock | 1 |
| Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
| Genzyme, a Sanofi Company | 1 |
| IRCCS Policlinico S. Donato | 1 |
| Mario Negri Institute for Pharmacological Research | 1 |
| Ospedale San Donato | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fabry Disease | 16 |
| Cardiomyopathy, Hypertrophic | 3 |
| Amyloid Neuropathies, Familial | 2 |
| Cardiomyopathies | 2 |
| Cardiomyopathy, Dilated | 2 |
| Death, Sudden, Cardiac | 2 |
| Angiokeratoma | 1 |
| Arrhythmogenic Right Ventricular Dysplasia | 1 |
| CADASIL | 1 |
| Cardiomyopathy, Restrictive | 1 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.